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SYNOPSIS	
Primary	intravenous	chemotherapy	followed	by	adjuvant	treatments	as	required	for	group	
D	retinoblastoma	resulted	in	the	present	study	with	an	eye	salvage	rate	of	63%	and	no	cases	
of	metastasis	or	death.		
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ABSTRACT	
Background	
Eye	salvage	rate	for	group	D	retinoblastoma	using	intravenous	chemotherapy	(IVC)	as	a	primary	
modality	is	less	than	50%.	To	report	on	13-years’	experience	with	the	use	of	primary	IVC	for	group	D	
retinoblastoma.		
Methods	
A	retrospective	analysis	of	64	group	D	eyes	(52	patients)	treated	with	primary	IVC,	from	
2002-2014.		
Results	
The	median	age	at	presentation	was	11.0	months	(mean:	18.6,	range:	0.6-144.0),	35	(67%)	
patients	had	bilateral	disease,	38	(73%)	germline	disease	and	8	(15%)	cases	were	familial.	In	
addition	to	IVC,	patients	received	a	median	number	of	3	treatments	(mean:	6,	range:	0-24),	
including	thermotherapy/cryotherapy,	plaque	radiotherapy,	intra-ophthalmic	artery	
chemotherapy	(IAC)	and/or	intra-vitreous	chemotherapy.	External	beam	radiotherapy	was	
used	in	5	eyes,	all	of	which	were	eventually	enucleated.	In	a	median	follow-up	time	of	55	
months	(mean:	64,	range:	14-156)	63%	of	eyes	were	salvaged.	By	Kaplan-Meier	survival	
analysis,	globe	salvage	rate	was	83%,	70%,	59%	and	45%	at	1,	3,	5	and	10	years,	
respectively.	There	were	no	cases	of	metastatic	spread	from	intraocular	retinoblastoma	and	
no	deaths.	IVC-related	adverse	events	included	febrile	neutropenia	in	21	(40%)	patients	and	
anaphylactic	reaction	to	carboplatin	in	2	(4%),	all	conservatively	resolved.	Of	the	patients	
receiving	IAC,	3rd	and	6th	nerve	palsy	was	documented	in	2	(10%)	and	1	(5%)	eyes,	
respectively.		
Conclusions		
Primary	IVC	for	group	D	eyes,	with	adjuvant	treatments	as	required,	was	found	to	be	a	safe	
and	efficient	approach,	achieving	63%	eye	salvage	rate,	no	metastatic	spread	from	
intraocular	retinoblastoma	and	no	deaths.	IAC	has	now	replaced	EBRT	as	a	successful	
salvage	treatment.	
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INTRODUCTION	
The	treatment	of	intraocular	retinoblastoma	has	advanced	over	the	years	and	a	wide	range	
of	options	is	available.	Over	the	last	2	decades	one	of	the	major	treatment	options	has	been	
intravenous	chemotherapy	(IVC)	and	the	classification	of	intraocular	retinoblastoma	has	
changed	from	the	Reese-Ellsworth	(R-E),1	which	predicted	success	from	radiotherapy,	to	the	
International	Classification	of	Retinoblastoma	(ICRB),2	which	predicts	success	in	the	era	of	
chemotherapy.	In	this	schema,	the	most	advanced	cases,	Group	E,	are	usually	enucleated	
and	Groups	A	to	C	demonstrate	over	90%	chance	of	success	of	globe	salvage	using	local	
treatments	with	IVC.3	It	is	the	Group	D	eyes	that	are	the	challenging	cases	in	terms	of	eye	
salvage.		
Since	external	beam	radiotherapy	(EBRT)	was	widely	abandoned	and	IVC	for	intraocular	
retinoblastoma	introduced,	the	latter	has	been	the	main	primary	treatment	for	group	D	
eyes	in	many	centres,4	achieving	up	to	47%	eye	salvage	rate.3	With	development	and	
popularisation	of	intra-ophthalmic	artery	chemotherapy	(IAC),5,6	this	treatment	has	found	
more	recent	favour	as	a	primary	treatment	for	group	D	eyes	due	to	its	selectivity	and	
reported	success	in	achieving	tumour	control,	even	being	used	in	some	centres	for	bilateral	
cases.7	However,	first	line	IAC	has	possible	drawbacks,	the	most	prominent	of	which	relates	
to	its	selectivity	for	the	eye,	potentially	allowing	systemic	spread.8,9	In	addition,	as	it	is	a	
modality	requiring	advanced	infrastructure	and	expertise,	it	is	not	available	in	all	centres.		
In	the	London	Retinoblastoma	Service	the	primary	treatment	used	for	the	majority	of	group	
D	retinoblastoma	patients	has	been	IVC.	Selected	patients	are	treated	by	primary	
enucleation,	but	attempts	to	preserve	the	globe	without	compromise	to	patient	survival	are	
being	increasingly	favoured.	In	the	UK,	IAC	is	used	mainly	as	a	salvage	treatment.			
The	goal	of	this	study	was	to	report	on	the	management	course	and	outcomes	of	group	D	
eyes	treated	initially	in	our	centre	with	IVC.		
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METHODS	
This	was	a	retrospective	chart	review	of	consecutive	group	D	retinoblastoma	cases,	
classified	according	to	the	ICRB,2	that	presented	to	the	Retinoblastoma	Service	at	the	Royal	
London	Hospital,	from	27.11.2002	–	17.12.2014,	and	treated	initially	with	IVC.	The	study	
was	approved	by	the	Barts	Health	NHS	Trust	institutional	review	board	(number	6622).		
	
Data	retrieved	from	clinical	notes	included	patients’	age,	gender,	inheritance	status	(i.e.	
retinoblastoma	family	history),	presenting	signs,	clinical	variables,	genetic	analysis,	
treatment	specifications	and	extraocular	complications.	Two	of	the	authors	(IDF	and	KCJ)	
examined	all	RetCam	images,	including	fluorescein	angiograms	when	available,	of	all	
patients,	analysed	the	scans	and	recorded	the	results.		
Cryotherapy,	transpupillary	thermotherapy	(TTT)	and	ruthenium	plaque	brachytherapy	were	
performed	at	the	discretion	of	the	treating	clinician.	For	cryotherapy,	a	cryosurgical	system	
(Mira,	Waltham,	MA,	USA)	was	used,	and	each	treatment	session	included	3	freeze-thaw	
cycles,	and	for	TTT	(Iris	Medical	OcuLight	SLx,	Iridex	Corporation,	Mountain	View,	CA,	USA),	
an	810nm	indirect	large	laser	spot	beam	was	used.	During	the	study	period,	overall	3	
physicians	treated	the	study	patients,	using	the	same	treatment	protocols.	Decision	to	
enucleate	an	eye	or	treat	with	chemotherapy	was	made	after	a	joint	consultation	between	
the	treating	ophthalmologist/s	and	medical	oncologist/s.	Implants	used	after	enucleations	
were	vicryl	mesh-coated	hydroxyapatite,	to	which	the	extraocular	muscles	were	attached,	
or	acrylic,	in	which	cases	a	myoconjunctival	technique	was	used.10	The	presence	of	high	risk	
features	for	systemic	spread	on	histopathological	evaluation11	prompted	treatment	with	
adjuvant	IVC.	IVC	for	intraocular	tumours	included	6	courses	of	vincristine,	etoposide	and	
carboplatin	(VEC),	given	via	a	central	venous	line,	approximately	every	3	weeks.	In	cases	in	
which	second-line	IVC	was	indicated,	or	in	cases	of	high	risk	features	on	histopathology	in	
enucleated	eyes,	the	protocol	included	ifosfamide,	vincristine	and	doxorubicin	(IVAd),	given	
for	4-6	courses.	The	technique	of	intra-vitreous	chemotherapy	(IViC)	was	previously	
described	and	the	agents	used	were	melphalan	and/or	topotecan.12	For	IAC,	the	agents	
used	were	melphalan,	topotecan	and/or	carboplatin,	and	the	technique	has	been	described	by	
our	centre	previously.13		
	
Statistical	Analysis	and	Study	Definitions	
All	calculations	were	performed	using	Microsoft	Excel	2013	software	(Microsoft	
Corporation,	Redmond,	WA)	and	SPSS	software	version	17.0	(SPSS,	Inc.,	Chicago,	IL).		
P-values	were	calculated	using	Chi-squared	function	and	T-Test,	and	survival	estimates	using	
Kaplan-Meier	analysis.	Early	treatment	failure	was	defined	as	insufficient	tumour	response	
(main	tumour	and/or	seeds),	requiring	change	in	management,	during	or	immediately	after	
IVC	cycles.		
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RESULTS	
Patient	characteristics	and	clinical	presentation	
There	were	104	group	D	retinoblastoma	eyes	of	92	patients	diagnosed	and	managed	in	our	
service	during	the	study	period.	Of	these,	40	(37.5%)	underwent	primary	enucleation.	The	
remaining	64	eyes	of	52	patients	(28	(54%)	males)	were	treated	by	means	of	primary	IVC	
and	these	comprise	the	present	study	cohort.	The	presentation	details	and	genetic	analysis	
of	the	study	patients	are	summarised	in	Table	1	and	results	of	clinical	examination	at	
presentation	in	Table	2.		
Table	1.	Demographics,	variables	at	presentation	and	genetic	analysis	of	52	Group	D	retinoblastoma	
patients	(64	eyes)	treated	by	primary	intravenous	chemotherapy.		
Parameter	 N=52	patientsa	 %	
Gender		
										Male		
										Female	
	
28	
24	
	
54	
46	
Presenting	signs		
										Leucocoria	
										Strabismus	
										Leucocoria	and	strabismus	
										Otherb	
	
29	
13	
4	
6	
	
56	
25	
8	
12	
Uni/bilateral	retinoblastoma	
										Unilateral	at	presentation	(at	final	follow-up)	
										Bilateral	at	presentation	(at	final	follow-up)	
	
18	(17)	
34	(35)	
	
35	(33)	
65	(67)	
Contralateral	eye’s	classification	in	bilateral	cases	(n=35)	
										0c	
										A	
										B	
										C	
										D	
										E	
	
1	
5	
6	
5	
12	
6	
	
3	
14	
17	
14	
34	
17	
Age	first	symptoms	noticed	(months)d	
										Median	(mean,	range)	
	
9.0	(17.1,	0.1-142.0)	
	
Age	at	diagnosis	(months)	
										Median	(mean,	range)	
	
All	cohort	11.0	(18.6,	0.6-144.0)	
Unilateral	cases	14.0	(31.6,	1.5-144.0)	
Bilateral	cases	10.0	(12.3,	0.6-108.0)	
	
Presumed	diagnosis	made	locally	–	final	diagnosis	(days)	
										Median	(mean,	range)		
	
6.0	(5.7,	1.0-36.0)	
	
Genetics	and	inheritance	
										Blood	mutation	found	in	
										Sporadic	
																				Unilateral	
																				Bilateral	
										Familial	
																				Unilateral	
																				Bilateral	
	
38	
44	
										16	
										28	
8	
										1	
										7	
	
73	
85	
36	
64	
15	
12.5	
87.5	
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																				Trilaterale	 										1	 12.5	
a	Data	presented	for	the	whole	cohort,	unless	otherwise	stated.		
b	Other	presenting	signs	included	periorbital	swelling	in	one	patient,	floaters	and	flashing	lights	in	3	
children	>8-year	old	and	nystagmus	in	2	patients.		
c	A	familial	case	that	presented	as	D/0,	however	developed	new	tumours	in	the	non-D	eye	nearly	8	months	
after	first	presentation.			
d	Retrospectively	reported	by	the	parents/guardians.		
e	Bilateral	disease	plus	pinealblastoma.		
	
Table	2.	Clinical	examination	at	presentation	of	64	Group	D	retinoblastoma	eyes	(52	patients)	treated	by	
primary	intravenous	chemotherapy.		
Parameter	 N=64	eyes	 %	
Laterality		
										Right	eye	
										Left	eye	
	
40	
24	
	
63	
38	
Horizontal	corneal	diameter	of	the	D	eye	(mm)	
										Median	(mean,	range)	
	
11.5	(11.4,	10.0-12.5)	
	
Tumour	focality		
										Unifocal	
										Multifocal	
	
41	
23	
	
64	
36	
Tumour	dimensions	(mm)	
										Median	(mean,	range)	
	
Height:	9.7	(10.1,	4.4-19.2)	
Base:	13.0	(12.6,	7.8-19.0)	
	
Quadrants	of	retinal	detachment		
										No	detachment	
										Local	
										1	
										2	
										3	
										4	
	
6	
12	
3	
7	
7	
29	
	
9	
19	
5	
11	
11	
45	
Optic	disc	obscured		
										Not	obscured	
										Obscured	
	
17	
47	
	
27	
73	
Fovea	involvement		
										Not	involved	
										Sub-foveal	fluid	
										Foveal	tumour	
	
11	
11	
42	
	
17	
17	
66	
Retinoblastoma	seeds		
										No	seeds	
										Sub-retinal	
										Vitreous	
										Both	
	
9	
41	
28	
14	
	
14	
64	
44	
22	
	
Leucocoria	was	the	most	common	presenting	feature	(56%),	followed	by	strabismus	(25%).	
Of	the	52	study	patients,	34	(65%)	presented	with	bilateral	retinoblastoma	and	the	
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remaining	18	(35%)	with	unilateral	disease.	One	familial	case	that	presented	as	unilateral	
Group	D	retinoblastoma	later	developed	retinal	tumours	in	the	non-D	eye.	Of	the	bilateral	
cases,	bilateral	D	was	the	most	common	combination	(34%).		
The	median	age	of	diagnosis	was	11.0	months	(mean:	18.6,	range:	0.6-144.0).	Eight	patients	
(15%)	had	positive	family	history,	1	(12.5%)	of	which	presented	with	trilateral	
retinoblastoma.	On	genetic	analysis,	available	approximately	3	months	after	first	diagnosis,	
in	38	patients	(73%)	a	blood	RB1	mutation	was	found.		
Multifocal	tumours	were	found	in	23	(36%)	eyes,	a	total	retinal	detachment	in	29	(45%)	
eyes,	the	optic	disc	was	obscured	in	47	(73%)	eyes,	foveal	tumour	involvement	in	42	(66%)	
eyes	and	retinoblastoma	seeds,	subretinal	and/or	vitreous,	were	detected	in	55	(86%)	eyes,	
in	≥97%	eyes	seeds	were	spread	in	a	diffuse	manner.	 
	
Management	and	outcomes	
Table	3	summarizes	the	management	course	of	the	study	patients.	Of	the	bilateral	cases,	
there	were	6	that	presented	with	group	D	in	1	eye	and	group	E	in	the	fellow	eye.	All	of	these	
had	the	group	E	eye	enucleated	and	histology	evaluated	prior	to	commencing	IVC.		
Table	3.	Management	summary	of	64	Group	D	retinoblastoma	eyes	(52	patients)	treated	with	primary	
intravenous	chemotherapy.		
Parameter	 Number=64	eyes	 %	
Primary	intravenous	chemotherapy	regimen	a	
										Number	of	treatments	
																				Median	(mean,	range)		
										Time	range	(days)	
																				Median	(mean,	range)	
	
	
6	(6,	2-6)	
	
120	(123,	33-160)	
	
Early	treatment	failure	(no	response	to	chemotherapy)	 8	 12.5	
Total	number	of	additional	treatments	b	
										Median	(mean,	range)	
	
3	(6,	0-24)	
	
Number	of	eyes	having	additional	treatments	
										No	additional	treatments	
										Additional	diode	laser	and/or	cryotherapy	
																				During	systemic	chemotherapy	courses	
										Ruthenium	plaque	radiotherapy	
										Intra-ophthalmic	artery	chemotherapy	
																				Median	number	of	treatments	(mean,	range)	
										Intravitreal	chemotherapy	
																				Median	number	of	treatments	(mean,	range)	
										Second	line	systemic	chemotherapy	
										External	beam	radiotherapy	
	
3	
50	
										23	
12	
20c	
										3	(3,	1-6)	
4d	
										2	(3,	1-6)	
2	
5	
	
5	
78	
46	
19	
31	
	
6	
	
3	
8	
a	Vincristine,	etoposide,	carboplatin.		
b	Including	diode	laser,	cryotherapy,	plaque	radiotherapy	and	salvage	intravenous	chemotherapy,	excluding	
external	beam	radiotherapy	and	secondary	enucleation.		
c	First	patients	treated	in	2009.		
d	First	patient	treated	in	2014.			
Fabian	et	al	/	Primary	Intravenous	Chemotherapy	for	Group	D	Retinoblastoma	
	 9	
	
Standard	protocol	of	6	cycles	of	intravenous	VEC	was	used	in	all	patients,	except	3,	whose	
tumours	failed	to	respond	to	IVC.	Of	these,	2	were	switched	to	IAC,	but	underwent	
enucleation	after	2	treatments	due	to	further	tumour	progression,	and	one	was	enucleated	
after	5	VEC	cycles.		
Altogether,	early	treatment	failure	occurred	in	8	(12.5%)	eyes,	5	of	which	underwent	
secondary	enucleation	immediately	after	completion	of	the	6th	IVC	cycle.	On	statistical	
analysis,	tumour	focality	and	horizontal	corneal	diameter	of	the	D	eye	were	the	only	
variables	associated	with	early	treatment	failure	(Table	4).	In	detail,	100%	of	eyes	with	
multifocal	retinoblastoma	showed	good	response	to	primary	IVC	compared	to	81.5%	of	eyes	
with	unifocal	tumours	(p=0.043),	and	larger	horizontal	corneal	diameter	was	found	to	
associate	with	higher	chances	for	early	treatment	failure	(p=0.012).	Of	note,	in	no	case	was	
a	difference	found	in	corneal	horizontal	diameter	between	eyes	of	the	same	patient.		
Table	4.	Primary	intravenous	chemotherapy	in	64	group	D	eyes	of	52	patients:	favourable	response	versus	
early	treatment	failure.		
Parameter	 Favourable	response	(56	
eyes	of	45	patients,	%)	
Early	treatment	failurea	(8	
eyes	of	7	patients,	%)	
P	
Gender	
										Male	
										Female	
	
22	(49)	
23	(51%)	
	
6	(86)	
1	(14)	
0.107	
Presenting	signs		
										Leucocoria	
										Strabismus	
										Leucocoria	and	strabismus	
										Otherb	
	
26	(58)	
10	(22)	
4	(9)	
5	(10)	
	
3	(43)	
3	(43)	
0	(0)	
1	(14)	
0.583	
Laterality		
										Right	eye	
										Left	eye	
	
34	(61)	
22	(39)	
	
6	(75)	
2	(25)	
0.699	
Age	at	diagnosis	(months)	
										Median	(mean,	range)	
	
11.0	(15.4,	0.6-108.0)	
	
24.0	(39.0,	3.0-144.0)	
0.257	
Horizontal	corneal	diameter	of	the	
D	eye	(mm)	
										Median	(mean,	range)	
	
	
11.0	(11.3,	10.0-12.5)	
	
	
12.0	(12.0,	11.5-12.5)	
0.012	
Tumour	focality		
										Multifocal	
										Unifocal	
	
33	(59)	
23	(41)	
	
8	(100)	
0	(0)	
0.043	
Tumour	dimensions	(mm)	
										Median	(mean,	range)	
	
Height:	9.3	(9.9,	4.4-19.2)	
Base:	12.2	(12.3,	7.8-19.0)	
	
Height:	12.4	(12.6,	11.5-13.9)	
Base:	14.4	(14.7,	14.1-15.5)	
	
0.598	
0.671	
Retinal	detachment	
										Detached	
										Not	detached	
	
50	(89)	
6	(11)	
	
8	(100)	
0	(0)	
1.000	
Optic	disc	obscured		
										Obscured	
										Not	obscured	
	
40	(71)	
16	(29)	
	
7	(88)	
1	(13)	
0.670	
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Fovea	involvement		
										Sub-foveal	fluid	
										Foveal	tumour	
										Not	involved	
	
10	(18)	
36	(64)	
10	(18)	
	
1	(13)	
6	(75)	
1	(13)	
0.837	
Retinoblastoma	sub-retinal	seeds		
										Present	
										Not	present	
	
36	(64)	
20	(36)	
	
5	(63)	
3	(38)	
1.000	
Retinoblastoma	vitreous	seeds		
										Present	
										Not	present	
	
25	(45)	
31	(55)	
	
3	(38)	
5	(63)	
1.000	
a	Defined	as	no	regression	of	the	intraocular	tumour	components	(main	tumour	and/or	seeds),	during	or	
immediately	after	systemic	chemotherapy	cycles,	requiring	change	in	management.		
	
Of	the	64	eyes	treated	with	IVC,	95%	required	additional	treatments,	mainly	in	the	form	of	
TTT	and/or	cryotherapy.	Additional	chemotherapy	treatments	included	IAC	in	20	(31%)	eyes,	
IViC	in	4	(6%)	eyes	and	second	line	IVC	in	2	(3%).	Five	(8%)	were	treated	with	lens-sparing	
EBRT;	however	all	eventually	had	to	undergo	secondary	enucleation	(in	4	(80%)	cases	the	
underlying	reason	was	uncontrolled	tumours	and	in	1	(20%)	development	of	iris	
neovascularization	and	non-clearing	vitreous	haemorrhage).	
The	median	follow-up	time	for	the	whole	cohort	was	55	months	(mean:	64,	range:	14-156),	
in	which	time	40	(63%)	eyes	were	salvaged.	The	median	time	from	last	intervention	to	last	
follow-up	visit	was	24	months	(mean:	38,	range:	0-156).	Kaplan-Meier	survival	analysis	
showed	an	overall	globe	salvage	rate	of	83%,	70%,	59%	and	45%	at	1,	3,	5	and	10	years,	
respectively.	Figure	1	shows	the	cumulative	eye-survival	according	to	Kaplan-Meier	analysis,	
and	in	addition	a	sub-analysis	of	eyes	that	resulted	with	early	treatment	failure	and	those	
treated	with	salvage	IAC.	On	statistical	analysis,	none	of	the	clinical	variables	emerged	as	
significant	risk	factors	for	secondary	enucleation.	Of	the	24	enucleated	eyes,	11	(46%)	had	
been	treated	with	salvage	IAC,	but	IAC	was	not	found	to	be	a	significant	risk	factor,	nor	a	
protective	one,	for	secondary	enucleation	(p=0.118).	Of	the	4	eyes	treated	with	IViC,	only	
one	underwent	secondary	enucleation.		
Of	the	24	secondary	enucleations,	42%	were	performed	during	the	first	year	of	follow-up,	
58%	after	the	1st	year,	38%	after	the	2nd	year	and	25%	after	the	3rd	year.	Indications	for	
secondary	enucleation	included	tumour	relapse	at	the	optic	nerve	head,	neovascularization	
of	the	iris	with	vitreous	haemorrhage,	tumour	relapse	in	the	anterior	chamber,	multiple	
subretinal/vitreous	seeds	with/without	subtotal/total	retinal	detachment.	Most	cases	
showed	a	combination	of	these	indications.	Six	(25%)	secondary	enucleations	were	
performed	before	IAC	was	available	and	the	rest	(75%)	after.	To	note,	20	(31%)	eyes	
presented	before	2009,	i.e.	first	IAC	use,	however	all	were	further	followed-up	during	the	
period	that	IAC	was	available,	and	in	4	(20%)	of	this	early	cohort,	IAC	was	used.	Of	the	22	
patients	(42%)	that	underwent	secondary	enucleation,	4	(8%)	who	had	bilateral	
retinoblastoma,	eventually	underwent	bilateral	enucleation.		
Of	the	24	secondary	enucleated	eyes,	5	(21%)	showed	high-risk	features	on	histopathology	
and	were	treated	with	adjuvant	IVC	because	of	risk	of	secondary	spread.		
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Extraocular-related	adverse	events	
IVC	related	adverse	events	included	Grade	3	febrile	neutropenia	in	21	(40%)	patients	and	
Grade	3	anaphylaxis	after	carboplatin	administration	in	2	(4%).	IAC	related	adverse	events	
included	3rd	and	6th	nerve	palsies	in	2	(10%)	and	1	(5%)	patients,	respectively.	In	all	of	these	
cases,	conservative	management	or	observation	resulted	with	complete	resolution.	In	2	
(10%)	cases	IAC	was	abandoned	due	to	technical	difficulties	in	catheterization.	No	
complications	or	related	adverse	events	were	recorded	after	IViC.		
No	case	of	metastatic	spread	from	intraocular	retinoblastoma	and	no	cases	of	death	
occurred	during	the	study	period.	However,	1	case	with	trilateral	disease	was	also	treated	
for	pinealoblastoma	that	had	metastasised	to	the	spine,	and	was	alive	at	the	end	of	this	
study	period.		
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DISCUSSION	
The	last	3	decades	have	witnessed	huge	developments	in	the	management	of	
retinoblastoma,	with	several	new	modalities	becoming	available.	This	has	necessitated	a	
rethink	of	the	classification	of	intraocular	disease	from	the	R-E	classification	that	predicted	
globe	salvage	in	the	era	of	EBRT,1	to	the	ICRB,	which	was	developed	in	the	era	of	
chemotherapy.2	The	present	study	bridges	an	era	in	our	centre	after	the	establishment	of	
IVC	for	retinoblastoma,4,14–16	when	EBRT	was	used	for	salvage,	to	the	emergence	of	IAC	for	
salvage.	This	was	a	large	cohort	of	64	group	D	eyes	followed-up	for	a	median	time	of	nearly	
5	years	with	an	eye	salvage	rate	of	63%.	This	is	significantly	higher	than	previous	similar	
studies.3,17–25		Before	IAC,	Shields	et	al.	reported	a	globe	salvage	rate	of	47%	in	group	D	eyes	
treated	by	primary	IVC,3	the	highest	success	rate	achieved	in	the	pre-IAC	era.	Of	note,	
Shields	et	al.	used	the	Philadelphia	version	of	the	IRCB,3	whereas	we	used	slightly	different	
criteria	to	define	D	eyes,	according	to	the	Children’s	Hospital	Los	Angeles	scheme,2	and	it	
was	shown	that	such	discrepancies	may	adversely	impact	attempts	to	compare	treatment	
outcomes.26	Nevertheless,	this	does	not	fully	explain	the	disparity	in	salvage	rates	between	
the	2	studies.		
In	a	previous	study	from	1995-2003	from	our	centre	on	group	D	heritable	retinoblastoma	
treated	with	primary	IVC	with	median	follow-up	of	30	months,	found	that	11/18	eyes	(61%)	
were	salvaged,	with	5	eyes	requiring	salvage	with	EBRT.23	Since	then,	the	role	of	EBRT	has	
been	relegated	to	being	akin	to	treatment	failure,	especially	with	increased	risk	of	second	
cancers	in	patients	with	germline	retinoblastoma.27	Interestingly,	in	the	present	study,	
salvage	EBRT	was	used	in	5	eyes,	all	in	the	early	cases,	prior	to	the	use	of	IAC,	and	in	all,	
treated	eyes	were	eventually	enucleated.	Presumably,	the	longer	follow-up	in	this	report	
allowed	for	more	definitive	outcomes.	These	findings,	in	addition	to	the	known	risk	
associated	with	EBRT,27	strengthen	the	approach	that	EBRT	should	have	a	diminished	role	in	
treating	intraocular	retinoblastoma.			
IAC	and	more	recently	IViC	injections	are	important	adjuncts	and	are	important	in	achieving	
the	relatively	high	salvage	rate	in	the	present	cohort.	Interestingly,	neither	was	found	to	be	
a	significant	protective	factor	for	eye	salvage.	As	for	IViC,	this	is	not	surprising,	as	it	was	first	
used	in	the	current	cohort	in	2014	and	only	in	4	eyes.	IAC	however	was	first	introduced	in	
2009	and	used	in	20	eyes	in	this	study.	A	reasonable	explanation	would	be	that	IAC	was	
used	as	a	salvage	treatment	initially	in	more	resistant	cases,	and	11	of	these	had	to	undergo	
secondary	enucleation.		
Yousef	et	al.,	in	a	systematic	review	on	IAC,	reported	a	total	of	67%	success	rate,	when	used	
as	second	line	therapy,	but	for	all	eye	groups,8	clearly	different	to	the	present	study	that	
concentrates	on	D	eyes	only.	Eye	salvage	for	advanced	retinoblastoma	in	their	analysis	was	
found	to	be	57%,	when	IAC	was	used	as	first	and	second	line	and	for	ICRB	groups	D	and	E.8	
Shields	et	al.	reported	67%	eye	retention	in	a	small	case	series	of	6	D	eyes	treated	with	
primary	IVC	followed	by	IAC.28	Abramson	et	al.	recently	published	their	results	on	D	eyes	
treated	with	first	line	IAC	(n=47)	and	reported	on	85.1%	success	rate.9	In	their	study	the	
median	follow-up	time	was	30	months,	in	12	(24%)	eyes	it	was	under	a	year,	and	in	7	(14%)	
2-6	months.	In	our	study	nearly	60%	of	secondary	enucleations	were	performed	after	the	
first	year	of	follow-up	and	nearly	40%	after	the	second	year,	so	it	is	possible	that	later	
relapse	might	lead	to	more	enucleations	and	a	lower	overall	globe	salvage.	Conversely,	it	is	
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possible	that	we	may	be	able	to	increase	our	globe	retention	rates	by	earlier	use	of	salvage	
IAC,	as	our	initial	cases	were	treated	with	this	modality	as	a	last	resort.	Overall	then,	results	
from	the	present	and	other	studies	show	that	IAC,	when	indicated,	is	a	powerful	tool	as	an	
adjunct	to	primary	IVC	for	group	D	retinoblastoma,	enabling	retention	of	a	greater	number	
of	eyes	compared	to	IVC	alone	or	with	the	use	of	additional	local	consolidation.		
We	tried	to	understand	whether	certain	features	would	sub-classify	Group	D	into	eyes	that	
were	more	likely	to	succeed	with	IVC	or	would	be	higher	risk	for	enucleation.	None	of	the	
variables	emerged	as	significant	risk	factors	for	secondary	enucleation.	This	is	not	surprising,	
as	per	definition,	D	eye	tumours	hold	common	features,	including	tumour	size	and	the	
presence	of	retinal	detachment	and	seeding.	To	note,	in	2	relatively	large	cohort	studies	on	
retinoblastoma	eyes	treated	by	primary	IVC,20,29	group	D	eyes	were	analysed	as	part	of	a	
larger	cohort	containing	additional	ICRB	groups	and	no	sub-analysis	was	performed.	In	the	
literature,	there	are	no	reports	of	specific	risk	factors	for	secondary	enucleation	of	D	eyes	
treated	initially	with	IVC.		
Eight	eyes	resulted	with	early	treatment	failure	and	eventually	secondary	enucleation.	
Salvage	IAC	was	not	available	for	all,	but	when	used	for	2	of	these	cases,	it	also	failed	to	
achieve	a	beneficial	effect.	There	is	only	scant	literature	on	retinoblastoma	that	does	not	
respond	to	IVC	and	that	necessitates	immediate	change	in	management.	In	a	retrospective	
analysis	by	Gunduz	et	al.,30	unresponsive	disease	was	defined	as	persistence	of	retinal	
tumours,	vitreous	or	subretinal	seeds	after	the	second	IVC	cycle,	with	no	appreciable	sign	of	
regression.	Recurrent	disease	was	defined	as	regrowth	of	tumours	any	time	after	an	initial	
favourable	response.	Of	105	eyes	(all	R-E	classification	groups)	10	(10%)	eyes	were	
unresponsive	to	treatment.	On	statistical	analysis,	however,	unresponsive	cases	were	
combined	with	recurrent	ones,	precluding	specific	insight	into	the	former	subgroup.	
Interestingly,	in	the	present	study,	eyes	with	unifocal	tumours	and	those	with	relatively	
larger	horizontal	corneal	diameters	(in	both	eyes)	were	found	to	be	at	significant	risk	for	
early	treatment	failure.	We	have	no	reasonable	explanations	for	these	associations.	It	
should	also	be	mentioned,	that	detection	of	numerous	tumours,	usually	in	cases	of	genetic	
disease,	is	not	always	possible,	especially	in	D	eyes,	as	in	most	a	total	retinal	detachment	
can	limit	a	clear	view	and	ultrasound	is	only	partially	helpful	in	such	cases.		
In	3	eyes	(5%)	no	additional	treatments	to	IVC	were	needed	in	order	to	reach	tumour	
control	and	in	more	than	half	TTT	and/or	cryotherapy	were	given	after	completion	of	the	
chemotherapy	cycles.	There	is	no	consensus	on	the	use	of	adjuvant	therapies.	In	some	
reports	routine	use	of	consolidating	local	modalities	was	superior	to	chemotherapy	alone,31	
but	caution	is	sometimes	necessary	in	case	of	adverse	impact.32,33	This	argues	for	adjuvant	
treatments	given	only	when	indicated,	as	they	may	also	have	an	adverse	impact	on	the	
treated	eyes.		
The	extraocular	complications	and	adverse	events	related	to	IVC	reported	in	this	study	are	
in	the	spectrum	found	in	the	literature.34	This	is	also	the	case	regarding	IAC.13	For	both	
modalities	no	serious	or	life-threatening	events	were	recorded,	but	twice	there	was	an	
anaphylactic	reaction	to	systemic	carboplatin	that	responded	to	conservative	management.	
Metastatic	disease	from	intraocular	retinoblastoma	did	not	occur	in	any	of	the	cases,	an	
inherent	protective	feature	of	IVC	over	primary	IAC.8	The	high	globe	retention	rates	
reported	with	primary	IAC	for	group	D	retinoblastoma	(85%)	are	impressive,	but	there	was	a	
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6%	metastatic	rate	in	that	study.9	In	the	IVC	era	metastatic	rates	have	been	low,	so	the	
metastatic	risks	of	primary	IAC	may	temper	the	enthusiasm	for	this	technique	in	some	
centres.		
Limitations	of	this	study	include	mainly	its	retrospective	and	non-randomized	design.	Nearly	
40%	of	eyes	during	the	study	period	underwent	primary	enucleation	(hence	were	excluded	
from	this	analysis	of	chemotherapy	treated	eyes).	This	could	potentially	result	in	selection	
bias	if	the	more	advanced	group	D	eyes	were	enucleated.	Although	not	the	subject	of	the	
current	report,	we	compared	the	the	primary	enucleation	with	the	primary	IVC	cohort	(data	
not	shown),	and	found	that	the	enucleation	cases	were	selected	not	for	more	advanced	or	
complicated	disease,	but	rather		older	age	of	presentation	and	usually	unilateral	disease.	
These	reservations	should	be	taken	into	account	when	interpreting	the	results	of	the	
present	study.	Additional	limitations	are	inherent	to	the	clinical	examination	of	group	D	
retinoblastoma	eyes	and	include,	in	some	cases,	difficulty	in	assessing	the	number	of	
tumours	and	the	presence	of	subretinal	seeds	in	case	of	a	large	retinal	detachment.	In	
regard	to	insufficient	tumour	response	cases,	the	definite	criterion	to	be	included	in	this	
subgroup	was	change	in	management	during	or	immediately	after	IVC.	There	are	several	
tumour	features	that	can	change	in	respond	to	treatment	and	these	include,	among	others,	
size,	colour,	vascularization,	degree	of	calcification,	number	of	tumours,	and	density.	It	is	
the	combination	of	all	of	the	above	features	summed-up	on	clinical	examination	that	
dictates	whether	change	of	management	is	required.		
In	summary,	in	this	large	cohort	of	group	D	retinoblastoma	eyes,	primary	intravenous	
chemotherapy,	followed	by	additional	local	therapies,	tailored	as	per	clinical	need,	was	
found	to	be	an	efficient	and	safe	approach,	achieving	an	eye	salvage	rate	of	63%	in	a	median	
follow-up	time	of	nearly	5	years.	In	this	time	period	no	case	of	metastatic	spread	from	
intraocular	retinoblastoma	was	recorded	and	no	cases	of	death.	These	results	are	an	
improvement	on	those	reported	previously	for	group	D	eyes	treated	with	primary	
intravenous	chemotherapy,	and	are	partly	a	result	of	IAC,	that	was	added	as	a	salvage	
modality,	replacing	EBRT.	With	the	recent	addition	of	IViC,	both	locally-delivered	
chemotherapy	modalities,	used	as	powerful	adjuncts	to	primary	intravenous	chemotherapy,	
are	expected	to	further	improve	eye	salvage	rates	and	control	of	the	disease,	replacing	the	
use	of	EBRT.		
	
	 	
Fabian	et	al	/	Primary	Intravenous	Chemotherapy	for	Group	D	Retinoblastoma	
	 15	
ACKOWLEDGMENT	
We	gratefully	acknowledge	the	contribution	of	the	late	Dr	Judith	Kingston,	Consultant	
Paediatric	Oncologist	for	the	introduction	of	intravenous	chemotherapy	for	intraocular	
retinoblastoma,	including	in	the	patients	reported	herein.		
The	authors	indicate	no	funding	support	and	no	competing	interest.		
	
	 	
Fabian	et	al	/	Primary	Intravenous	Chemotherapy	for	Group	D	Retinoblastoma	
	 16	
REFERENCES	
1.		 REESE	AB,	ELLSWORTH	RM.	The	evaluation	and	current	concept	of	retinoblastoma	
therapy.	Trans	Am	Acad	Ophthalmol	Otolaryngol.	67:164-172.		
2.		 Linn	Murphree	A.	Intraocular	retinoblastoma:	the	case	for	a	new	group	classification.	
Ophthalmol	Clin	North	Am.	2005;18(1):41-53.	
3.		 Shields	CL,	Mashayekhi	A,	Au	AK,	et	al.	The	International	Classification	of	
Retinoblastoma	predicts	chemoreduction	success.	Ophthalmology.	
2006;113(12):2276-2280.		
4.		 Kingston	JE,	Hungerford	JL,	Madreperla	SA,	Plowman	PN.	Results	of	combined	
chemotherapy	and	radiotherapy	for	advanced	intraocular	retinoblastoma.	Arch	
Ophthalmol	(Chicago,	Ill		1960).	1996;114(11):1339-1343.		
5.		 Yamane	T,	Kaneko	A,	Mohri	M.	The	technique	of	ophthalmic	arterial	infusion	therapy	
for	patients	with	intraocular	retinoblastoma.	Int	J	Clin	Oncol.	2004;9(2):69-73.		
6.		 Abramson	DH,	Dunkel	IJ,	Brodie	SE,	Kim	JW,	Gobin	YP.	A	phase	I/II	study	of	direct	
intraarterial	(ophthalmic	artery)	chemotherapy	with	melphalan	for	intraocular	
retinoblastoma	initial	results.	Ophthalmology.	2008;115(8):1398-1404.	
7.		 Abramson	DH,	Shields	CL,	Munier	FL,	Chantada	GL.	Treatment	of	Retinoblastoma	in	
2015:	Agreement	and	Disagreement.	JAMA	Ophthalmol.	September	2015:1-7.		
8.		 Yousef	YA,	Soliman	SE,	Astudillo	PPP,	et	al.	Intra-arterial	Chemotherapy	for	
Retinoblastoma:	A	Systematic	Review.	JAMA	Ophthalmol.	March	2016.		
9.		 Abramson	DH,	Daniels	AB,	Marr	BP,	et	al.	Intra-Arterial	Chemotherapy	(Ophthalmic	
Artery	Chemosurgery)	for	Group	D	Retinoblastoma.	PLoS	One.	2016;11(1):e0146582.		
10.		 Shome	D,	Honavar	SG,	Raizada	K,	Raizada	D.	Implant	and	prosthesis	movement	after	
enucleation:	a	randomized	controlled	trial.	Ophthalmology.	2010;117(8):1638-1644.		
11.		 Kaliki	S,	Shields	CL,	Shah	SU,	Eagle	RC,	Shields	JA,	Leahey	A.	Postenucleation	adjuvant	
chemotherapy	with	vincristine,	etoposide,	and	carboplatin	for	the	treatment	of	high-
risk	retinoblastoma.	Arch	Ophthalmol	(Chicago,	Ill		1960).	2011;129(11):1422-1427.		
12.		 Munier	FL,	Gaillard	M-C,	Balmer		a.,	et	al.	Intravitreal	chemotherapy	for	vitreous	
disease	in	retinoblastoma	revisited:	from	prohibition	to	conditional	indications.	Br	J	
Ophthalmol.	2012;96(8):1078-1083.		
13.		 Muen	WJ,	Kingston	JE,	Robertson	F,	Brew	S,	Sagoo	MS,	Reddy	MA.	Efficacy	and	
complications	of	super-selective	intra-ophthalmic	artery	melphalan	for	the	treatment	
of	refractory	retinoblastoma.	Ophthalmology.	2012;119(3):611-616.		
14.		 Murphree	AL,	Villablanca	JG,	Deegan	WF,	et	al.	Chemotherapy	plus	local	treatment	in	
the	management	of	intraocular	retinoblastoma.	Arch	Ophthalmol	(Chicago,	Ill		1960).	
1996;114(11):1348-1356.		
15.		 Gallie	BL,	Budning	A,	DeBoer	G,	et	al.	Chemotherapy	with	focal	therapy	can	cure	
Fabian	et	al	/	Primary	Intravenous	Chemotherapy	for	Group	D	Retinoblastoma	
	 17	
intraocular	retinoblastoma	without	radiotherapy.	Arch	Ophthalmol	(Chicago,	Ill		
1960).	1996;114(11):1321-1328.		
16.		 Shields	CL,	De	Potter	P,	Himelstein	BP,	Shields	JA,	Meadows	AT,	Maris	JM.	
Chemoreduction	in	the	initial	management	of	intraocular	retinoblastoma.	Arch	
Ophthalmol	(Chicago,	Ill		1960).	1996;114(11):1330-1338.		
17.		 Bartuma	K,	Pal	N,	Kosek	S,	Holm	S,	All-Ericsson	C.	A	10-year	experience	of	outcome	in	
chemotherapy-treated	hereditary	retinoblastoma.	Acta	Ophthalmol.	2014;92(5):404-
411.		
18.		 Lim	FPM,	Soh	SY,	Iyer	JV,	Tan	AM,	Swati	H,	Quah	BL.	Clinical	profile,	management,	
and	outcome	of	retinoblastoma	in	singapore.	J	Pediatr	Ophthalmol	Strabismus.	
50(2):106-112.		
19.		 Berry	JL,	Jubran	R,	Kim	JW,	et	al.	Long-term	outcomes	of	Group	D	eyes	in	bilateral	
retinoblastoma	patients	treated	with	chemoreduction	and	low-dose	IMRT	salvage.	
Pediatr	Blood	Cancer.	2013;60(4):688-693.		
20.		 Gündüz	K,	Köse	K,	Kurt	RA,	et	al.	Retinoblastoma	in	Turkey:	results	from	a	tertiary	
care	center	in	Ankara.	J	Pediatr	Ophthalmol	Strabismus.	50(5):296-303.		
21.		 Shin	JY,	Kim	JH,	Yu	YS,	et	al.	Eye-preserving	therapy	in	retinoblastoma:	prolonged	
primary	chemotherapy	alone	or	combined	with	local	therapy.	Korean	J	Ophthalmol.	
2010;24(4):219-224.		
22.		 Gao	Y-J,	Qian	J,	Yue	H,	Yuan	Y-F,	Xue	K,	Yao	Y-Q.	Clinical	characteristics	and	treatment	
outcome	of	children	with	intraocular	retinoblastoma:	a	report	from	a	Chinese	
cooperative	group.	Pediatr	Blood	Cancer.	2011;57(7):1113-1116.		
23.		 Cohen	VML,	Kingston	J,	Hungerford	JL.	The	success	of	primary	chemotherapy	for	
group	D	heritable	retinoblastoma.	Br	J	Ophthalmol.	2009;93(7):887-890.		
24.		 Chung	SE,	Sa	HS,	Koo	HH,	Yoo	KH,	Sung	KW,	Ham	D-I.	Clinical	manifestations	and	
treatment	of	retinoblastoma	in	Korea.	Br	J	Ophthalmol.	2008;92(9):1180-1184.		
25.		 Zage	PE,	Reitman	AJ,	Seshadri	R,	et	al.	Outcomes	of	a	two-drug	chemotherapy	
regimen	for	intraocular	retinoblastoma.	Pediatr	Blood	Cancer.	2008;50(3):567-572.		
26.		 Novetsky	DE,	Abramson	DH,	Kim	JW,	Dunkel	IJ.	Published	international	classification	
of	retinoblastoma	(ICRB)	definitions	contain	inconsistencies--an	analysis	of	impact.	
Ophthalmic	Genet.	2009;30(1):40-44.		
27.		 Wong	FL,	Boice	JD,	Abramson	DH,	et	al.	Cancer	incidence	after	retinoblastoma.	
Radiation	dose	and	sarcoma	risk.	JAMA.	1997;278(15):1262-1267.		
28.		 Shields	CL,	Kaliki	S,	Al-Dahmash	S,	et	al.	Management	of	advanced	retinoblastoma	
with	intravenous	chemotherapy	then	intra-arterial	chemotherapy	as	alternative	to	
enucleation.	Retina.	33(10):2103-2109.		
29.		 Shields	CL,	Honavar	SG,	Meadows	AT,	et	al.	Chemoreduction	plus	focal	therapy	for	
retinoblastoma:	factors	predictive	of	need	for	treatment	with	external	beam	
Fabian	et	al	/	Primary	Intravenous	Chemotherapy	for	Group	D	Retinoblastoma	
	 18	
radiotherapy	or	enucleation.	Am	J	Ophthalmol.	2002;133(5):657-664.		
30.		 Gündüz	K,	Günalp	I,	Yalçindağ	N,	et	al.	Causes	of	chemoreduction	failure	in	
retinoblastoma	and	analysis	of	associated	factors	leading	to	eventual	treatment	with	
external	beam	radiotherapy	and	enucleation.	Ophthalmology.	2004;111(10):1917-
1924.		
31.		 Shields	CL,	Mashayekhi	A,	Cater	J,	et	al.	Macular	retinoblastoma	managed	with	
chemoreduction:	analysis	of	tumor	control	with	or	without	adjuvant	thermotherapy	
in	68	tumors.	Arch	Ophthalmol	(Chicago,	Ill		1960).	2005;123(6):765-773.		
32.		 Lee	TC,	Lee	S-W,	Dinkin	MJ,	Ober	MD,	Beaverson	KL,	Abramson	DH.	Chorioretinal	scar	
growth	after	810-nanometer	laser	treatment	for	retinoblastoma.	Ophthalmology.	
2004;111(5):992-996.		
33.		 Gombos	DS,	Cauchi	PA,	Hungerford	JL,	Addison	P,	Coen	PG,	Kingston	JE.	Vitreous	
relapse	following	primary	chemotherapy	for	retinoblastoma:	is	adjuvant	diode	laser	a	
risk	factor?	Br	J	Ophthalmol.	2006;90(9):1168-1172.		
34.		 Rizzuti	AE,	Dunkel	IJ,	Abramson	DH.	The	adverse	events	of	chemotherapy	for	
retinoblastoma:	what	are	they?	Do	we	know?	Arch	Ophthalmol	(Chicago,	Ill		1960).	
2008;126(6):862-865.		
	
	 	
Fabian	et	al	/	Primary	Intravenous	Chemotherapy	for	Group	D	Retinoblastoma	
	 19	
FIGURE	LEGEND	
Figure	1	–	Kaplan-Meier	estimates	of	globe	salvage	in	(A)	the	whole	cohort,	(B)	favourable	
initial	response	to	primary	intravenous	chemotherapy	(IVC)	versus	early	treatment	failure	
and	(C)	primary	IVC	versus	primary	IVC	and	salvage	intra-ophthalmic	artery	(IAC).		
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